Metastatic Hepatocellular Carcinoma (HCC) – Pipeline Review, H1 2012


April 19, 2012
45 Pages - SKU: GMD3866298
License type:
Table of Contents Search inside this report Related Reports
Introduction
Global Markets Direct Report Coverage
Metastatic Hepatocellular Carcinoma (HCC) Overview
Therapeutics Development
An Overview of Pipeline Products for Metastatic Hepatocellular Carcinoma (HCC)
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics under Development by Companies
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics under Investigation by Universities/Institutes
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics – Products under Development by Companies
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Metastatic Hepatocellular Carcinoma (HCC) Therapeutics Development
F. Hoffmann-La Roche Ltd.
Chugai Pharmaceutical Co. Ltd
Metastatic Hepatocellular Carcinoma (HCC) – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
RG7686 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sorafenib Tosylate + TH-302 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zavedos - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sorafenib1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sorafenib4 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sorafenib for Liver Metastasis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AZD6244 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GC33 + Nexavar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sorafenib + Everolimus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sutent - Drug Profile
Product Description
Mechanism of Action
R&D Progress
S-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
S-1 + Interferon Alpha - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sorafenib + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lenalidomide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HLA-A*2402 Restricted Antiangiogenic Peptide Vaccine Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics – Drug Profile Updates
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics – Discontinued Products
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics - Dormant Products
Metastatic Hepatocellular Carcinoma (HCC) – Product Development Milestones
Featured News & Press Releases
Apr 13, 2010: Endo, Penwest Enter Into Agreement With Barr To Settle Patent Litigation Over Opana ER
Jun 13, 2006: Nexavar Receives Fast Track Designation From FDA For Metastatic Liver Cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products Under Development for Metastatic Hepatocellular Carcinoma (HCC), H1 2012
Products under Development for Metastatic Hepatocellular Carcinoma (HCC) – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
F. Hoffmann-La Roche Ltd., H1 2012
Chugai Pharmaceutical Co. Ltd, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics – Drug Profile Updates
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics – Discontinued Products
Metastatic Hepatocellular Carcinoma (HCC) Therapeutics – Dormant Products
List of Figures
Number of Products under Development for Metastatic Hepatocellular Carcinoma (HCC), H1 2012
Products under Development for Metastatic Hepatocellular Carcinoma (HCC) – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012
 
Research assistance
We can help you find what you need. Call us or write us:
US: 800.298.5699
Int'l: +1.240.747.3093
Need help in your search?
 
Related Markets

Drug Discovery Reports
 
 

Share this report


Other tasks

 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!